Fate Therapeutics reports USD 2.08 million revenue for stock investors

Published on 10/20/2026 at 21:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 2.08 million against USD 2.05 million consensus. Fate Therapeutics stock costs EUR 1.85 on October 20, 2026.

Revenue and valuation facts

Fate Therapeutics reported USD 2.08 million in second-quarter 2026 revenue against USD 2.05 million consensus.
Adjusted earnings per share were minus USD 0.25 in the second quarter of 2026.
Fate Therapeutics stock costs EUR 1.85 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST.
Market capitalization stood at USD 243.6 million on October 20, 2026.

FATE, US31189P1021, Illustration mit AI erstellt.

Fate Therapeutics reported USD 2.08 million in second-quarter 2026 revenue, compared with USD 2.05 million consensus, according to BusinessQuant on October 12, 2026. The result gives investors a more concrete operating marker than the stock's recent valuation swings. After the Xetra close, the stock was trading at EUR 1.85 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST.

Revenue topped the estimate

The second-quarter revenue figure exceeded the USD 2.05 million consensus by USD 0.03 million, or 1.46 percent. The comparison is based on the actual revenue and the consensus estimate for the same quarter, rather than on a year-over-year comparison.

Fate Therapeutics is a clinical-stage biotechnology company developing programmed cellular immunotherapies for cancer and immune disorders. Its investor materials describe a pipeline built around cell-based therapies and ex vivo cell programming, according to Fate Therapeutics.

Valuation leaves little room for error

Fate Therapeutics had a market capitalization of USD 243.6 million on October 20, 2026. The structured market quote also showed a trailing price-to-earnings ratio of minus 1.99 and a 52-week range of USD 0.95 to USD 3.23. The current euro quote therefore sits between a recent low and high when viewed alongside the home-market range, but the currencies are not directly interchangeable.

The company reported adjusted earnings per share of minus USD 0.25 for the second quarter of 2026, matching the consensus figure cited by MarketBeat on October 9, 2026. That pairing of revenue above expectations and a loss in line with expectations keeps the financial picture focused on development progress and funding discipline.

Corporate calendar stays event driven

On October 12, 2026, Fate Therapeutics appointed Jamie Harrell as senior vice president for market development and commercial operations, according to the company's investor-relations page. The appointment followed the company's October 2, 2026 disclosure of employee inducement awards. Those dates provide the latest visible corporate milestones while the next report date remains outside the substantiated calendar shown in the cited company materials.

Stock price after the Xetra close

Fate Therapeutics stock was trading at EUR 1.85 at Lang & Schwarz on October 20, 2026 at 9:34 p.m. CEST. The Nasdaq-listed shares had a market capitalization of USD 243.6 million on the same date, while the company reported USD 2.08 million in second-quarter 2026 revenue.

The further course of trading is shown by the continuously updated real-time quote of Fate Therapeutics stock.